| 
          CCL21 and IL1β         | 
        
      | Vaxjo ID | 283 | 
        
      | Vaccine Adjuvant Name | CCL21 and IL1β | 
        
      | Adjuvant VO ID | VO_0005771 | 
        
      | Description | This is a recombinant fusion protein of human CCL21 (a chemokine) and a non-inflammatory epitope of IL1β (VQGEESNDK). It was codon-optimized and produced in transgenic tobacco (Nicotiana tabacum). It aims to function as a tumor immunotherapy adjuvant, particularly for breast cancer (MCF7 cell line) | 
        
      | Stage of Development | Research | 
        
      | Host Species for Testing | Mouse | 
        
      | Components | A codon-optimized ccl21/IL1β gene was designed and synthesized from human genes. | 
        
      | Structure | Fusion of CCL21 and IL1β epitope connected by EAAAK linker. 3D structure modeled using Modeller 9.24. Interacts with the CCR7 receptor on T-cells | 
        
      | Appearance | Protein purified from transgenic plant leaves; visualized by SDS-PAGE and western blotting. | 
        
      | Preparation | Synthesized using codon-optimized gene introduced into Agrobacterium tumefaciens, then transferred to tobacco leaves. Expressed under the pBI121 binary vector. Purified using Ni-IDA resin via His-tagSynthesized using codon-optimized gene introduced into Agrobacterium tumefaciens, then transferred to tobacco leaves. Expressed under the pBI121 binary vector. Purified using Ni-IDA resin via His-tag | 
        
      | Dosage | In vitro testing used concentrations of 2.5–10 μg/ml; optimal at 7.5 μg/ml for anti-cancer activity in MCF7 cells | 
        
      | Function | The results demonstrated a decrease in survival rate and metastasization of cancer cells in the presence of CCL21/IL1尾, and IC50 of CCL21 on MCF7 cells was less than that of non-recombinant protein.聽 | 
        
      | Safety | Predicted to be non-allergenic (AlgPred). Stability index supports protein stability. In vitro assays did not report cytotoxicity beyond targeted cancer cells | 
    	
	
	  | References | Marashi et al., 2022: Marashi H, Beihaghi M, Chaboksavar M, Khaksar S, Tehrani H, Abiri A. In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity. PloS one. 2022; 17(8); e0261101. [PubMed: 36037155]. |